Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 4/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.32 |
| ▸ | NMT1 | P30419 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.30 |
| ▸ | GRK2 | P25098 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29954268 | 1.00 | DGAT1 (0.39) | DGAT1KDM1AKDM1BNPC1SMN1; SMN2 | |
| SCHEMBL12412174 | 0.82 | DGAT1 (0.35) | DGAT1KDM1AKDM1BNPC1SMN1; SMN2 | |
| SCHEMBL1550445 | 0.77 | DGAT1 (0.39) | DGAT1KDM1AKDM1BNPC1SMN1; SMN2 | |
| SCHEMBL29954159 | 0.76 | ALOX15 (0.42) | SMN1; SMN2LMNAALDH1A1HPGDKMT2A | |
| SCHEMBL12136644 | 0.76 | ALDH1A1 (0.42) | SMN1; SMN2LMNAALDH1A1HPGDKMT2A | |
| SCHEMBL29953631 | 0.76 | ALDH1A1 (0.42) | SMN1; SMN2LMNAALDH1A1HPGDKMT2A | |
| SCHEMBL324210 | 0.73 | ALDH1A1 (0.35) | SMN1; SMN2LMNAALDH1A1ALOX12PYCR1 | |
| SCHEMBL10252634 | 0.73 | ESR1 (0.41) | — | |
| SCHEMBL12548054 | 0.73 | ALDH1A1 (0.33) | LMNAALDH1A1GAAKMT2ARECQL | |
| SCHEMBL13303832 | 0.73 | ALDH1A1 (0.33) | NPC1SMN1; SMN2RAB9AALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339936-A1 | COMPOUND HAVING KINASE INHIBITORY ACTIVITY | CYTOSINLAB THERAPEUTICS CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| US-20230150973-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20180205025-A1 | LIGHT EMITTING MATERIAL, MANUFACTURE METHOD THEREOF AND ORGANIC LIGHT EMITTING DIODE USING THE LIGHT EMITTING MATERIAL | SHENZHEN CHINA STAR OPTOELECTRONICS TECHNOLOGY CO., LTD. (CN) | 2018-07-19 | — | — | US | disclosed |
| US-20180201833-A1 | LIGHT EMITTING MATERIAL, MANUFACTURE METHOD THEREOF AND ORGANIC LIGHT EMITTING DIODE USING THE LIGHT EMITTING MATERIAL | SHENZHEN CHINA STAR OPTOELECTRONICS TECHNOLOGY CO., LTD. (CN) | 2018-07-19 | — | — | US | disclosed |
| US-20180186768-A1 | Antibacterial Compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2018-07-05 | — | — | US | disclosed |
| US-20180170901-A1 | LIGHT EMITTING MATERIAL, MANUFACTURE METHOD THEREOF AND ORGANIC LIGHT EMITTING DIODE USING THE LIGHT EMITTING MATERIAL | SHENZHEN CHINA STAR OPTOELECTRONICS TECHNOLOGY CO., LTD. (CN) | 2018-06-21 | — | — | US | disclosed |
| US-20180170894-A1 | LIGHT EMITTING MATERIAL, MANUFACTURE METHOD THEREOF AND ORGANIC LIGHT EMITTING DIODE USING THE LIGHT EMITTING MATERIAL | SHENZHEN CHINA STAR OPTOELECTRONICS TECHNOLOGY CO., LTD. (CN) | 2018-06-21 | — | — | US | disclosed |
| US-20180170900-A1 | LIGHT EMITTING MATERIAL, MANUFACTURE METHOD THEREOF AND ORGANIC LIGHT EMITTING DIODE USING THE LIGHT EMITTING MATERIAL | SHENZHEN CHINA STAR OPTOELECTRONICS TECHNOLOGY CO., LTD. (CN) | 2018-06-21 | — | — | US | disclosed |
| US-20180170893-A1 | LIGHT EMITTING MATERIAL, MANUFACTURE METHOD THEREOF AND ORGANIC LIGHT EMITTING DIODE USING THE LIGHT EMITTING MATERIAL | SHENZHEN CHINA STAR OPTOELECTRONICS TECHNOLOGY CO., LTD. (CN) | 2018-06-21 | — | — | US | disclosed |
| US-20180170899-A1 | LIGHT EMITTING MATERIAL, MANUFACTURE METHOD THEREOF AND ORGANIC LIGHT EMITTING DIODE USING THE LIGHT EMITTING MATERIAL | SHENZHEN CHINA STAR OPTOELECTRONICS TECHNOLOGY CO., LTD. (CN) | 2018-06-21 | — | — | US | disclosed |
| US-7638632-B2 | 4-Ethynyl (1,2-dicyanobenzene)-4'-Ethynylphenyl-1(4,5-dicyanobenzene); 1,4-Bis(4-pyridyl)butadiyne; 4-ethynyl(pyridine)-4'-ethynylnaphthalene-1-pyridine; self-assembled mono-, multilayers/ supramolecular objects; three-terminal devices; logic switches;nanoelectronic ; computers; wires; dielectrics | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-12-29 | — | — | US | disclosed |
| US-20090298867-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | CARSON JOHN R | 2009-12-03 | — | — | US | disclosed |
| US-20090291956-A1 | SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)-IMIDAZO[1,2-b][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME | INCYTE CORPORATION | 2009-11-26 | — | — | US | disclosed |
| US-7589103-B2 | Especially 2-aminocarbonyl-9-(thio)xanthenylidene-8-aza-bicyclo[3.2.1] octane derivatives are used in pharmaceutical and veterinary compositions for treating mild to severe pain and various diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-09-15 | — | — | US | disclosed |
| US-20090030218-A1 | Method For Producing Aminoalcohol Derivative Having Biphenyl Group | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-01-29 | — | — | US | disclosed |
| US-7368449-B2 | 2-alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | MERCK PATENT GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| US-20070232620-A1 | 3-Aminoindazoles | MERCK PATENT GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| US-20070215866-A1 | Novel molecular structures with controllable electron conducting properties | E. I. DU PONT DE NEMOURS AND COMPANY | 2007-09-20 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170899-A1 | LIGHT EMITTING MATERIAL, MANUFACTURE METHOD THEREOF AND ORGANIC LIGHT EMITTING DIODE USING THE LIGHT EMITTING MATERIAL | TPMT, UFM1, UBE2M | DGAT1 1643/4885KDM1A 831/4885KDM1B 503/4885 |
| US-20070215866-A1 | Novel molecular structures with controllable electron conducting properties | TYR, MITF, CRY2 | DGAT1 1383/4885KDM1A 4330/4885KDM1B 4250/4885 |
| US-20090298867-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | DGAT1 1826/4885KDM1A 1934/4885KDM1B 2477/4885 |
| US-20180201833-A1 | LIGHT EMITTING MATERIAL, MANUFACTURE METHOD THEREOF AND ORGANIC LIGHT EMITTING DIODE USING THE LIGHT EMITTING MATERIAL | TPMT, UFM1, UBE2M | DGAT1 1759/4885KDM1A 1116/4885KDM1B 709/4885 |
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | SGK1, SGK2, SGK3 | DGAT1 1034/4885KDM1A 2951/4885KDM1B 3067/4885 |
| US-20180170893-A1 | LIGHT EMITTING MATERIAL, MANUFACTURE METHOD THEREOF AND ORGANIC LIGHT EMITTING DIODE USING THE LIGHT EMITTING MATERIAL | UBE2M, UFM1, AUP1 | DGAT1 1407/4885KDM1A 573/4885KDM1B 301/4885 |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | DGAT1 1961/4885KDM1A 4374/4885KDM1B 4471/4885 |
| US-20180170900-A1 | LIGHT EMITTING MATERIAL, MANUFACTURE METHOD THEREOF AND ORGANIC LIGHT EMITTING DIODE USING THE LIGHT EMITTING MATERIAL | TPMT, UFM1, UBE2M | DGAT1 1643/4885KDM1A 831/4885KDM1B 503/4885 |
| US-20180205025-A1 | LIGHT EMITTING MATERIAL, MANUFACTURE METHOD THEREOF AND ORGANIC LIGHT EMITTING DIODE USING THE LIGHT EMITTING MATERIAL | TPMT, UFM1, UBE2M | DGAT1 1643/4885KDM1A 831/4885KDM1B 503/4885 |
| US-20180170894-A1 | LIGHT EMITTING MATERIAL, MANUFACTURE METHOD THEREOF AND ORGANIC LIGHT EMITTING DIODE USING THE LIGHT EMITTING MATERIAL | UBE2M, UFM1, UFL1 | DGAT1 1490/4885KDM1A 819/4885KDM1B 492/4885 |
| US-20090291956-A1 | SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)-IMIDAZO[1,2-b][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME | ABL1, MET, ABL2 | DGAT1 3406/4885KDM1A 443/4885KDM1B 254/4885 |
| US-20230339936-A1 | COMPOUND HAVING KINASE INHIBITORY ACTIVITY | FLT3, ERBB2, ABL1 | DGAT1 3280/4885KDM1A 1269/4885KDM1B 951/4885 |
| US-20180186768-A1 | Antibacterial Compounds | FDPS, SQOR, NDUFS3 | DGAT1 1695/4885KDM1A 4449/4885KDM1B 4404/4885 |
| US-20090030218-A1 | Method For Producing Aminoalcohol Derivative Having Biphenyl Group | ALDH7A1, DDC, ADH5 | DGAT1 926/4885KDM1A 700/4885KDM1B 387/4885 |
| US-20230150973-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | AR, UTS2R, ESRRA | DGAT1 2681/4885KDM1A 1249/4885KDM1B 1301/4885 |
| US-20180170901-A1 | LIGHT EMITTING MATERIAL, MANUFACTURE METHOD THEREOF AND ORGANIC LIGHT EMITTING DIODE USING THE LIGHT EMITTING MATERIAL | TPMT, UFM1, UBE2M | DGAT1 1643/4885KDM1A 831/4885KDM1B 503/4885 |
| US-20070232620-A1 | 3-Aminoindazoles | SGK3, SGK1, SGK2 | DGAT1 994/4885KDM1A 2694/4885KDM1B 2204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.